This is all great news -- and yes, this is power alley stuff, for us. In any event, here's the latest:
. . .While late-stage, big-ticket acquisitions remain possibilities for Gilead, the pharma is not as pressed as its peers to ink major deals to beef up its product pipeline.
“We may not have the urgency of other companies in this sector,” CEO Daniel O’Day told investors in a call Tuesday afternoon to present the company’s full-year 2025 earnings results. But, he added, “we’re very proactive and disciplined.”
However, the pharma isn’t completely closing its doors on takeovers. O’Day noted that Gilead will “continue to add to our pipeline with appropriate M&A over the course of the coming years.”
Analysts at BMO Capital Markets echoed the sentiment, stating in a note to investors Wednesday morning that M&A for Gilead would be “nice to have” but not a necessity. If M&A were on the table, the analysts would look for activity “in core areas: liver disease, oncology, and inflammation. . . .”
Onward, smiling into a warming sunshine. . . be excellent to one another.
नमस्ते
No comments:
Post a Comment